ProCE Banner Activity


TROP-2 in Breast Cancer: How to Integrate ADCs Into Clinical Practice


Watch this on-demand webcast from a live meeting series on the optimal use of TROP-2 antibody–drug conjugates in the treatment of advanced triple-negative breast cancer and HR-positive/HER2-negative metastatic breast cancer.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: November 09, 2023

Expiration: November 08, 2024



Mabel Mardones

Mabel Mardones, MD

Physician Partner
Rocky Mountain Cancer Centers
USON Breast Cancer Pathways Task Force
Executive Committee Member for Breast Cancer Research 
Sarah Cannon Research Institute
Nashville, Tennessee 

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This educational program is intended for oncology physicians, nurses, pharmacists, physician associates, and other healthcare professionals caring for breast cancer patients.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of the oncology multidisciplinary care team to apply and explain available clinical data on novel and emerging therapies to individualize care for patients with metastatic breast cancer eligible for treatment with TROP2-targeted therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Elucidate the biological significance of TROP-2 in breast cancer, its prevalence, and the reasoning behind utilizing TROP-2–targeted ADCs

  • Evaluate and differentiate the distinct mechanisms of action among approved and emerging TROP-2–targeted ADCs

  • Formulate personalized treatment strategies incorporating TROP-2–targeting ADCs for patients with previously treated TNBC or endocrine-resistant HR+/HER2- MBC considering current and emerging efficacy and safety data and practical adverse event management strategies

  • Assess early data and ongoing clinical trials evaluating TROP-2–targeting ADCs in breast cancer and use this information to refer appropriate individuals for study participation 


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Mabel Mardones, MD

Physician Partner
Rocky Mountain Cancer Centers
USON Breast Cancer Pathways Task Force
Executive Committee Member for Breast Cancer Research 
Sarah Cannon Research Institute
Nashville, Tennessee 

Mabel Mardones, MD: consultant/advisor/speaker: Agendia, AstraZeneca, Epic Sciences, Genentech, Lilly, Puma, Sanofi, Seattle Genetics, Stemline.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Susan J. Moench, PhD, PA-C and Krisit K. Orbaugh, MSN, NP, AOCNP, as noted below.

Susan J. Moench, PhD, PA-C: independent contractor: Gilead, Merck.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 09, 2023, through November 08, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 


Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-283-H01-P 
Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education
Joint AccreditationClinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until November 08, 2024. PAs should only claim credit commensurate with the extent of their participation.